Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris
NCT ID: NCT05536193
Last Updated: 2022-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
34 participants
INTERVENTIONAL
2022-09-10
2023-09-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Acne lesions, which may be papules, pustules, or nodules commonly affecting face, chest and back therefore acne patients may suffer from emotional distress due to its chronicity and potential outcomes which include physical scars and persistent hyperpigmentation.
The pathophysiology of AV involves four factors: abnormal follicular keratinization, hyperseborrhea, Cutibacterium acnes proliferation in the pilosebaceous unit and inflammatory mediators released into the skin.
Diet is considered to be one of the main factors influencing the induction and aggravation of acne, though this is still debatable. Previous researches have focused on glycemic load, and hyperinsulinemia which lead to an increase in the concentration of insulin-like growth factor (IGF-1), which has been reported to affect androgen metabolism and lipogenesis Additionally, IGF-1 has been shown to upregulate inflammatory cytokines. A correlation between the severity of acne and the level of serum IGF-1 has also been reported. Previous clinical studies showed that a low glycemic diet can decrease both the size of the sebaceous gland and the number of inflammatory lesions
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Metformin Versus Topical Ketotifen in Melasma Treatment
NCT06942390
A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris
NCT02395549
Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients
NCT05096312
The Benefit of a Deep Cleansing Gel in the Management of Mild to Moderate Truncal Acne
NCT05584150
Efficacy and Tolerance of Formula 609613 37 in Acneic Patients
NCT05469880
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chemical peeling is a safe, efficacious, and cost-effective procedure for treating various skin disorders and for enhancing cosmetic appearance. The principle of peeling involves controlled chemical injury to the skin in order to promote it to rejuvenate, leading to smoothening of the skin and improvement of its surface texture .
As patients become more concerned about the risks and side-effects of acne medications such as antibiotics and isotretinoin, other options are needed .
Metformin is an oral antihyperglycemic agent often used to treat overweight type 2 diabetic patients. It decreases hepatic glucose output and increases glucose utilization by muscles and adipocytes by increasing insulin sensitivity .
Notably, metformin has been shown to suppress the mammalian target of rapamycin complex (mTORC1) activity . mTORC, also known as the mechanistic target of rapamycin, is a central cell growth regulating kinase that forms large molecular complexes in all eukaryotic cells. Rapamycin is an mTORC1-specific inhibitor, which complexes with the FK506-binding 12 kDa protein (FKBP12). Rapamycin analogs have been used clinically to treat a number of human diseases, including cancer. A wide range of both extra- and intracellular signals, including growth factors, nutrient status and stress conditions, have been shown to regulate mTORC1 to control cell growth .
Hence, it is plausible that metformin through inhibition of mTORC1 improves acne as AV is one of the mechanistic target of rapamycin complex 1 (mTORC1)-driven diseases. Moreover, metformin has been suggested for the treatment of other insulin resistant-related skin disorders such as hirsutism, hidradenitis suppurativa, and acanthosis nigricans .
In order to get a benefit from the anti-inflammatory effect of metformin on the skin, the best option is to enhance its dermal effects, therefore, its side effects will be less through the topical administration route .
Actually, by applying a topical form of this drug on acne spots, mTORC1 over activation in skin cells can be inhibited which leads to disappearance of acne spots .
Salicylic acid (SA) is a safe and efficacious peeling agent for a number of dermatological and cosmetic problems, including acne vulgaris .
SA peels soften the stratum corneum and cause skin shedding by loosening the intracellular matrix and corneocyte connections which can lead to an improvement in non-inflammatory comedones . Also, SA inhibits the arachidonic acid cascade leading to a decrease in inflammatory lesions .
In our study, we chose the emulgel formulation as a topical metformin form to increase the efficacy and absorption in treatment of AV. Emulgel used will be optimized for biocompatibility, consistency and chemical compatibility with metformin.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Topical Metformin Emulgel and salicylic acid
Topical Metformin Emulgel and salicylic acid
Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).
Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
Other Names:
• 2-hydroxybenzoic acid
Insulin- Like growth factor (ILGF-1)
3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topical Metformin Emulgel and salicylic acid
Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).
Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
Other Names:
• 2-hydroxybenzoic acid
Insulin- Like growth factor (ILGF-1)
3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients older than 18 years of age.
* Patients with mild and moderate AV.
* Patients with Fitzpatrick skin type III, IV and V.
Exclusion Criteria
* Patients under treatment with contraceptive pills or received any kinds of systemic or topical acne medication in the last 2 months (isotretinoin, antibiotics, topical products) or corticosteroid, lithium, growth hormone, systemic metformin, vitamin B12, whey proteins, and estrogenic-progestogens.
* History of hypertrophic/keloid scar formation.
* Pregnancy and lactation.
* Recurrent herpes infection.
* Subjects with diseases that affect IGF-1 levels such as diabetes, metabolic syndrome, and acromegaly.
* Conditions that affect liver or thyroid function, celiac disease and inflammatory bowel diseases.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ola Ahmed Elminshawy
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012 Oct 15;86(8):734-40.
Han XD, Oon HH, Goh CL. Epidemiology of post-adolescence acne and adolescence acne in Singapore: a 10-year retrospective and comparative study. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1790-1793. doi: 10.1111/jdv.13743. Epub 2016 Jul 12.
Hazarika N, Archana M. The Psychosocial Impact of Acne Vulgaris. Indian J Dermatol. 2016 Sep-Oct;61(5):515-20. doi: 10.4103/0019-5154.190102.
Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29.
Kim H, Moon SY, Sohn MY, Lee WJ. Insulin-Like Growth Factor-1 Increases the Expression of Inflammatory Biomarkers and Sebum Production in Cultured Sebocytes. Ann Dermatol. 2017 Feb;29(1):20-25. doi: 10.5021/ad.2017.29.1.20. Epub 2017 Feb 3.
Kwon HH, Yoon JY, Hong JS, Jung JY, Park MS, Suh DH. Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial. Acta Derm Venereol. 2012 May;92(3):241-6. doi: 10.2340/00015555-1346.
Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment Modalities for Acne. Molecules. 2016 Aug 13;21(8):1063. doi: 10.3390/molecules21081063.
Rendon MI, Berson DS, Cohen JL, Roberts WE, Starker I, Wang B. Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing. J Clin Aesthet Dermatol. 2010 Jul;3(7):32-43.
Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1329-35. doi: 10.1111/jdv.12116. Epub 2013 Feb 26.
Yuan HX, Guan KL. Structural insights of mTOR complex 1. Cell Res. 2016 Mar;26(3):267-8. doi: 10.1038/cr.2016.10. Epub 2016 Jan 22.
Arif T. Salicylic acid as a peeling agent: a comprehensive review. Clin Cosmet Investig Dermatol. 2015 Aug 26;8:455-61. doi: 10.2147/CCID.S84765. eCollection 2015.
Lin AN, Nakatsui T. Salicylic acid revisited. Int J Dermatol. 1998 May;37(5):335-42. doi: 10.1046/j.1365-4362.1998.00452.x. No abstract available.
Lee HS, Kim IH. Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatol Surg. 2003 Dec;29(12):1196-9; discussion 1199. doi: 10.1111/j.1524-4725.2003.29384.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMEVSSA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.